Citations

Clear

813 citation(s) found for "He, Helen".

Abstract 145: CRISPRi-Perturb-seq In Endothelial Cells Links Atherosclerosis Risk Loci To Novel Klf2/4 Regulatory Genes
Gupta, Rajat M. , Schnitzler, Gavin R., Kang, Helen , Fang, Shi, Lee, Vivian S. , Zheng, Tony, Barry, Aurelie , Angom, Ramcharan Singh , Lee-Kim, Vivian, Ma, Rosa, Zhou, Ronghao , Mukhopadhyay, Debabrata , Engreitz, J

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | October 2, 2023 | Volume: 43 | Issue: Suppl_1 | Pages: No page available

10.1161/atvb.43.suppl_1.145 Get It

Introduction: Genome-wide association studies (GWAS) have discovered >300 associations for CAD. Few loci are functionally characterized and may represent new mechanisms of disease. Hypothesis: Can an unbiased transcriptional screen for the >2000 candidate GWAS genes in endothelial cells (ECs) identify causal genes and disease-relevant pathways at CAD GWAS loci. Methods: We applied CRISPRi-Perturb-seq to knock down expression of genes within 500 Kb of coronary artery disease GWAS loci (2,300 genes in total) and measure their transcriptomic effects using single-cell RNA-seq. Validation of candidate causal genes was conducted in primary human ECs and zebrafish. Results: We identified 50 programs of co-expressed genes, which represent core cellular pathways (i.e. ribosome biogenesis) and 13 EC-specific pathways such as flow response and angiogenesis. The EC-specific programs show the greatest contribution to CAD heritability. 5 EC-specific programs have the greatest number of GWAS candidate genes. We find that 43 of 306 CAD GWAS signals converge onto these 5 gene programs, and all are regulated by genes in the cerebral cavernous malformations (CCM) pathway—which coordinates KLF2/4 transcriptional responses in endothelial cells, but has not been linked to CAD risk. The strongest regulator of these programs is TLNRD1 , which we show is a new CAD gene and novel regulator of the CCM pathway. TLNRD1 loss-of-function alters actin organization and barrier function in endothelial cells in vitro , and heart development in zebrafish in vivo . Conclusions: High-throughput functional analysis of 2,300 genes proximal to CAD GWAS loci prioritized pathways—such as angiogenesis and EC migration—that are regulated by multiple risk SNPs. Our study identifies new genes that likely influence risk for CAD, identifies convergence of CAD genes into certain pathways in endothelial cells, and prioritizes study of genes in the CCM-signaling pathway for contribution to CAD risk.
Knee Pain In A Recreational Runner
Jorgensen, Matthew S., Shah, Neil P. , Nadwodny, Jeffrey , Pujalte, George

Mayo Clinic

Medicine & Science in Sports & Exercise | September 26, 2023 | Volume: 55 | Issue: 9S | Pages: 946-946

10.1249/01.mss.0000988644.46720.56 Get It

Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
Desai, Sanjal H. , Evens, Andrew M. , Šýkorová, Alice , Bachanová, Veronika , Goyal, Gaurav , Dorritie, Kathleen , Azzi, Jacues, Kenkre, Vaishalee P. , Chang, Cheryl , Michalka, Jozef , Ansell, Stephen M. , Fusco, Brendon , Hatic, Haris, Saba, Raya , Harris, Elyse I., Wagner‐Johnston, Nina D. , Arai, Sally , Nowakowski, Grzegorz S. , Móciková, Heidi , Jagadeesh, Deepa , Blum, Kristie A. , Diefenbach, Catherine , Iyengar, Siddharth , Rappazzo, Katherine , Choi, Yun Young , Advani, Ranjana H. , Micallef, Ivana N. , Evens, Andrew M , Goyal, Guarav , Dorritie, Kathleen , Sumransub, Nuttavut , Ibrahim, Uroosa , Wagner-Johnston, Nina , Arai, Sally , Mocikova, Heidi , Prochazka, Vit , Micallef, Ivana, Bachanova, Veronika , Advani, Ranjana H , Desai, Sanjal , Diefenbach, Catherine S , Spinner, Michael A. , Kahl, Brad S. , Shah, Harsh , Baidoun, Firas , Procházka, Vít

Mayo Clinic

Blood Advances | September 20, 2023 | Volume: 7 | Issue: 23 | Pages: 7295-7303

10.1182/bloodadvances.2023011205 | PMID 37729621 Get It

Abstract In the pre–novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.
The Inherited KRAS -variant as a Biomarker of Cetuximab Response in NSCLC
Weidhaas, Joanne B. , Hu, Chen , Komaki, Ritsuko , Masters, Gregory A. , Blumenschein, George R. , Chang, Joe Y. , Lu, Bo , Dicker, Adam P. , Bogart, Jeffrey A. , Garces, Yolanda I. , Narayan, Samir , Robinson, Clifford G. , Kavadi, Vivek S. , Koprowski, Christopher D. , Welsh, James W. , Gore, Elizabeth , MacRae, Robert M. , Bradley, Jeffrey D. , Greenberger, Joel S , Koprowski, Christopher D , Welsh, James , MacRae, Robert M , Paulus, Rebecca , Bradley, Jeffrey , Robinson, Clifford , Dicker, Adam P , Paulus, Rebecca

Mayo Clinic

Cancer Research Communications | September 20, 2023 | Volume: 3 | Issue: 10 | Pages: 2074-2081

10.1158/2767-9764.crc-23-0084 | PMID 37728512 Get It

Abstract Purpose: RTOG 0617 was a phase III randomized trial for patients with unresectable stage IIIA/IIIB non–small cell lung cancer comparing standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy and chemotherapy, plus or minus cetuximab. Although the study was negative, based on prior evidence that patients with the KRAS-variant, an inherited germline mutation, benefit from cetuximab, we evaluated KRAS-variant patients in RTOG 0617. Experimental Design: From RTOG 0617, 328 of 496 (66%) of patients were included in this analysis. For time-to-event outcomes, stratified log-rank tests and multivariable Cox regression models were used. For binary outcomes, Cochran—Mantel–Haenzel tests and multivariable logistic regression models were used. All statistical tests were two sided, and a P value <0.05 was considered significant. Results: A total of 17.1% (56/328) of patients had the KRAS-variant, and overall survival rates were similar between KRAS-variant and non-variant patients. However, there was a time-dependent effect of cetuximab seen only in KRAS-variant patients—while the hazard of death was higher in cetuximab-treated patients within year 1 [HR = 3.37, 95% confidence interval (CI): 1.13–10.10, P = 0.030], death was lower from year 1 to 4 (HR = 0.33, 95% CI: 0.11–0.97, P = 0.043). In contrast, in non-variant patients, the addition of cetuximab significantly increased local failure (HR = 1.59, 95% CI: 1.11–2.28, P = 0.012). Conclusions/Discussion: Although an overall survival advantage was not achieved in KRAS-variant patients, there is potential impact of cetuximab for this genetic subset of patients. In contrast, cetuximab seems to harm non-variant patients. These findings further support the importance of genetic patient selection in trials studying the addition of systemic agents to radiotherapy. Significance: The KRAS-variant is the first functional, inherited miRNA-disrupting variant identified in cancer. Our findings support that cetuximab has a potentially beneficial impact on KRAS-variant patients treated with radiation. The work confirms prior evidence that KRAS-variant patients are a subgroup who are especially sensitive to radiation. These findings further support the potential of this class of variants to enable true treatment personalization, considering the equally important endpoints of response and toxicity.
TRAPPC6B biallelic variants cause a neurodevelopmental disorder with TRAPP II and trafficking disruptions
Almousa, Hashem , Lewis, Sara A. , Bakhtiari, Somayeh , Nordlie, Sandra H., Pagnozzi, Alex M. , Magee, Helen, Efthymiou, Stéphanie , Heim, Jennifer, Anwar, Najwa, Maqbool, Shazia , Rahman, Fatima , Neilson, Derek , Vemuri, Anusha, Jin, Sheng Chih , Yang, Xiao‐Ru, Heidari, Abolfazl, Trimouille, Aurélien , Thauvin‐Robinet, Christel , Liu, James, Bruel, Ange‐Line , Tomoum, Hoda , Shata, Mennatallah Osama , Hashem, Mais O, Karimiani, Ehsan Ghayoor , Lingappa, Lokesh , Baruah, Debangana, Ebrahimzadeh, Farnoosh , Van‐Gils, Julien , Faivre, Laurence , Galehdari, Hamid, Sadeghian, Saeid , Mohammad, Rahema, Smagt, Jasper J. van der , Qari, Alya , Akar, Halil Tuna , Bilgüvar, Kaya , Mignot, Cyril , Keren, Boris , Raveli, Claudia, Afenjar, Alexandra , Kaat, Laura Donker , Slegtenhorst, Marjon van, Alkuraya, Fowzan S. , Houlden, Henry , Padilla‐Lopez, Sergio , Maroofian, Reza , Sacher, Michael , Kruer, Michael C. , Cornejo, Patricia , Jin, Sheng Chih , Zamani, Mina , Sadeghian, Saeid , Alkuraya, Fowzan S , Houlden, Henry , Maroofian, Reza , Sacher, Michael , Faivre, Laurence , Donker Kaat, Laura , Zaki, Maha S. , Gassen, Koen L.I. van , Hashem, Mais O, Toosi, Mehran Beiraghi , Yeşil, Gözde , Galehdari, Hamid , Shariati, Gholamreza , Vincent, John B. , Innes, A. Micheil , Dursun, Ali , Özgül, Rıza Köksal , Bürglen, Lydie

Mayo Clinic

Brain | September 15, 2023 | Volume: 147 | Issue: 1 | Pages: 311-324

10.1093/brain/awad301 | PMID 37713627 Get It

Abstract Highly conserved transport protein particle (TRAPP) complexes regulate subcellular trafficking pathways. Accurate protein trafficking has been increasingly recognized to be critically important for normal development, particularly in the nervous system. Variants in most TRAPP complex subunits have been found to lead to neurodevelopmental disorders with diverse but overlapping phenotypes. We expand on limited prior reports on TRAPPC6B with detailed clinical and neuroradiologic assessments, and studies on mechanisms of disease, and new types of variants. We describe 29 additional patients from 18 independent families with biallelic variants in TRAPPC6B. We identified seven homozygous nonsense (n = 12 patients) and eight canonical splice-site variants (n = 17 patients). In addition, we identified one patient with compound heterozygous splice-site/missense variants with a milder phenotype and one patient with homozygous missense variants. Patients displayed non-progressive microcephaly, global developmental delay/intellectual disability, epilepsy and absent expressive language. Movement disorders including stereotypies, spasticity and dystonia were also observed. Brain imaging revealed reductions in cortex, cerebellum and corpus callosum size with frequent white matter hyperintensity. Volumetric measurements indicated globally diminished volume rather than specific regional losses. We identified a reduced rate of trafficking into the Golgi apparatus and Golgi fragmentation in patient-derived fibroblasts that was rescued by wild-type TRAPPC6B. Molecular studies revealed a weakened interaction between mutant TRAPPC6B (c.454C>T, p.Q152*) and its TRAPP binding partner TRAPPC3. Patient-derived fibroblasts from the TRAPPC6B (c.454C>T, p.Q152*) variant displayed reduced levels of TRAPPC6B as well as other TRAPP II complex-specific members (TRAPPC9 and TRAPPC10). Interestingly, the levels of the TRAPPC6B homologue TRAPPC6A were found to be elevated. Moreover, co-immunoprecipitation experiments showed that TRAPPC6A co-precipitates equally with TRAPP II and TRAPP III, while TRAPPC6B co-precipitates significantly more with TRAPP II, suggesting enrichment of the protein in the TRAPP II complex. This implies that variants in TRAPPC6B may preferentially affect TRAPP II functions compared to TRAPP III functions. Finally, we assessed phenotypes in a Drosophila TRAPPC6B-deficiency model. Neuronal TRAPPC6B knockdown impaired locomotion and led to wing posture defects, supporting a role for TRAPPC6B in neuromotor function. Our findings confirm the association of damaging biallelic TRAPPC6B variants with microcephaly, intellectual disability, language impairments, and epilepsy. A subset of patients also exhibited dystonia and/or spasticity with impaired ambulation. These features overlap with disorders arising from pathogenic variants in other TRAPP subunits, particularly components of the TRAPP II complex. These findings suggest that TRAPPC6B is essential for brain development and function, and TRAPP II complex activity may be particularly relevant for mediating this function.
Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy
Lin, Heather , Diego, Emilia J. , Yang, Wei , Valero, Vicente , Mitchell, Melissa P. , White, Richard L. , Rauch, Gaiane M., Kuerer, Henry M. , Group, Exceptional Responders Study, Moseley, Tanya W. , Leung, Jessica WT, Huang, Monica L. , Arribas, Elsa , Parra, Raquel FD van la, Teshome, Mediget , Hwang, Rosa F. , Miggins, Makesha, Piotrowski, Matthew J., Refinetti, Ana P, Ehlers, Richard A., Colen, Jessica Suarez, Loveland‐Jones, Catherine, Lesnikowski, Beth Ann, Samiian, Laila, Chong, Clayton, Arribas, Elsa M , Johnson, Helen Margaret , Shen, Yu , Krishnamurthy, Savitri , Smith, Benjamin D. , Lucci, Anthony , Sun, Susie X. , Shaitelman, Simona Flora , Boughey, Judy C. , Rauch, Gaiane M. , Group, Exceptional Responders Study, Candelaria, Rosalind P. , Adrada, Beatriz E. , Hunt, Kelly K. , Bedrosian, Isabelle

Mayo Clinic

JAMA Network Open | September 14, 2023 | Volume: 6 | Issue: 9 | Pages: e2333933

10.1001/jamanetworkopen.2023.33933 | PMID 37707811 Get It

ImportancePatients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials.ObjectiveTo evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfort and health-related quality of life (HRQOL) among patients who elected to enroll in a clinical trial evaluating radiotherapy alone, without breast surgery, for invasive breast cancers with exceptional response to neoadjuvant systemic therapy (NST).Design, Setting, and ParticipantsProspective, single-group, phase 2 clinical trial at 7 US medical centers. Women aged 40 years or older with invasive cT1-2 N0-1 M0 triple-negative or human epidermal growth factor receptor 2 (ERBB2)–positive breast cancer with no pathologic evidence of residual disease following standard NST enrolled from March 6, 2017, to November 9, 2021. Validated PRO measures were administered at baseline and 6, 12, and 36 months post-radiotherapy. Data were analyzed from January to February 2023.InterventionsPRO measures included the Decision Regret Scale (DRS), Functional Assessment of Cancer Therapy—Lymphedema (FACT-B+4), and Breast Cancer Treatment Outcomes Scale (BCTOS).Main Outcomes and MeasuresChanges in PRO measure scores and subscores over time.ResultsAmong 31 patients, the median (IQR) age was 61 (56-66) years, 26 (84%) were White, and 26 (84%) were non-Hispanic. A total of 15 (48%) had triple-negative disease and 16 (52%) had ERBB2-positive disease. Decisional comfort was high at baseline (median [IQR] DRS score 10 [0-25] on a 0-100 scale, with higher scores indicating higher decisional regret) and significantly increased over time (median [IQR] DRS score at 36 months, 0 [0-20]; P < .001). HRQOL was relatively high at baseline (median [IQR] FACT-B composite score 121 [111-134] on a 0-148 scale, with higher scores indicating higher HRQOL) and significantly increased over time (median [IQR] FACT-B score at 36 months, 128 [116-137]; P = .04). Perceived differences between the affected breast and contralateral breast were minimal at baseline (median [IQR] BCTOS score 1.05 [1.00-1.23] on a 1-4 scale, with higher scores indicating greater differences) and increased significantly over time (median [IQR] BCTOS score at 36 months, 1.36 [1.18-1.64]; P < .001). At 36 months postradiotherapy, the cosmetic subscore was 0.45 points higher than baseline (95% CI, 0.16-0.74; P = .001), whereas function, pain, and edema subscores were not significantly different than baseline.Conclusions and RelevanceIn this nonrandomized phase 2 clinical trial, analysis of PROs demonstrated an overall positive experience for trial participants, with longitudinal improvements in decisional comfort and overall HRQOL over time and minimal lasting adverse effects of therapy.Trial RegistrationClinicalTrials.gov Identifier: NCT02945579
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors
Abuzakhm, Sonia, Sukrithan, Vineeth , Fruth, Briant, Qin, Rui , Strosberg, Jonathan , Hobday, Timothy J. , Reidy‐Lagunes, Diane , Kindler, Hedy L. , Kim, George P., Knox, Jennifer J. , Kaubisch, Andreas , Villalona‐Calero, Miguel A. , Erlichman, Charles , Shah, Manisha H. , Strosberg, Jonathan R , Knox, Jennifer J , Sukrithan, Vineeth , Semrad, Thomas John , Chen, Helen

Mayo Clinic

Endocrine-Related Cancer | September 13, 2023 | Volume: 30 | Issue: 11 | Pages: No page available

10.1530/erc-22-0301 | PMID 37702588 Get It

We assessed the efficacy and safety of combining bevacizumab with temsirolimus in patients with advanced extra-pancreatic neuroendocrine tumors. This NCI-sponsored multicenter, open-label, phase II study (NCT01010126) enrolled patients with advanced, recurrent, or metastatic extra-pancreatic neuroendocrine tumors. All patients were treated with temsirolimus and bevacizumab until disease progression or unacceptable toxicity. Temsirolimus 25 mg was administered i.v. on days 1, 8, 15, and 22 and bevacizumab 10 mg/kg i.v. on days 1 and 15 of a 4-week cycle. Discontinuation of temsirolimus or bevacizumab did not require discontinuation of the other agent. The primary endpoints were objective response rate and 6-month progression-free survival rate. Fifty-nine patients were enrolled in this study, and 54 were evaluated for efficacy and adverse events. While median progression-free survival was 7.1 months, the median duration of treatment with temsirolimus was 3.9 months and that with bevacizumab was 3.5 months. The objective response rate of combination therapy was 2%, and 6-month progression-free survival was 48%. The most frequently reported grade 3–4 adverse events included fatigue (13%), hypertension (13%), and bleeding (13%). Close to 54% of the patients discontinued treatment due to adverse events, refusal of further treatment, or treatment delays. Three deaths occurred in the study, of which two were due to treatment-related bowel perforations. Given the minimal efficacy and increased toxicity seen with the combination of bevacizumab and temsirolimus, we do not recommend the use of this regimen in patients with advanced extra-pancreatic neuroendocrine tumors.
Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Ettinger, David S. , Wood, Douglas E. , Stevenson, James, Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 6, 2023 | Volume: 21 | Issue: 9 | Pages: 961-979

10.6004/jnccn.2023.0045 | PMID 37673108 Get It

Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM). The NCCN Guidelines for PeM provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated PeM. The diagnosis of PeM may be delayed because PeM mimics other diseases and conditions and because the disease is so rare. The pathology section was recently updated to include new information about markers used to identify mesothelioma, which is difficult to diagnose. The term “malignant” is no longer used to classify mesotheliomas, because all mesotheliomas are now defined as malignant.
P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
Ajufo, Helen, Harrison, Claire , Palmer, Jeanne , Derkach, Andrii, Roman‐Torres, Karisse, Buckley, Sarah , Rampal, Raajit K. , Bewersdorf, Jan Philipp , Palandri, Francesca , Mascarenhas, John , Gerds, Aaron T. , Kiladjian, Jean‐Jacques , Дмитрович, Деркач Андрій

Mayo Clinic

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e44640da

10.1097/01.hs9.0000971016.44640.da Get It

P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY
Mateos, María‐Victoria , Martin, Tom, Stewart, Keith, Diels, Joris , Thilakarathne, Pushpike, Perualila, Nolen Joy , Cabrieto, Jedelyn, Erler-Yates, Nichola, Jackson, Carolyn C. , Schecter, Jordan M. , Strulev, Vadim, Haddad, Imène , Filho, Octavio Costa, Pacaud, Lida , Weisel, Katja C , Berdeja, Jesús G. , Jakubowiak, Andrzej , Jagannath, Sundar , Lin, Yi , Ghilotti, Francesca , Einsele, Hermann , Moreau, Philippe

Mayo Clinic

HemaSphere | August 22, 2023 | Volume: 7 | Issue: S3 | Pages: e641482c

10.1097/01.hs9.0000970592.64148.2c Get It